Holen Sie sich die Stockscreener-App
12.48
3.06%
0.37
Handel nachbörslich:
12.47
-0.010
-0.08%
Schlusskurs vom Vortag:
$12.11
Offen:
$12.18
24-Stunden-Volumen:
309.64K
Relative Volume:
0.67
Marktkapitalisierung:
$1.69B
Einnahmen:
$7.50M
Nettoeinkommen (Verlust:
$-81.89M
KGV:
0.2354
EPS:
53.0176
Netto-Cashflow:
$-63.58M
1W Leistung:
-13.27%
1M Leistung:
-27.23%
6M Leistung:
+52.75%
1J Leistung:
+149.10%
1-Tages-Spanne:
$11.88
$12.58
1-Wochen-Bereich:
$11.88
$14.29
52-Wochen-Spanne:
$4.60
$22.00
Mesoblast Ltd Adr Stock (MESO) Company Profile
Firmenname
Mesoblast Ltd Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie MESO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MESO
Mesoblast Ltd Adr
|
12.48 | 1.69B | 7.50M | -81.89M | -63.58M | 53.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Mesoblast Ltd Adr Stock (MESO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-23 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-24 | Hochstufung | Maxim Group | Hold → Buy |
| 2024-08-29 | Hochstufung | Jefferies | Hold → Buy |
| 2024-07-23 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-08-31 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-07 | Herabstufung | Maxim Group | Buy → Hold |
| 2023-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-08-04 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-03-09 | Eingeleitet | William Blair | Outperform |
| 2022-12-06 | Herabstufung | Jefferies | Buy → Hold |
| 2022-09-06 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-07 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-12-22 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-12-04 | Herabstufung | Chardan Capital Markets | Neutral → Sell |
| 2020-10-22 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-08-14 | Bestätigt | Maxim Group | Buy |
| 2020-05-28 | Bestätigt | H.C. Wainwright | Buy |
| 2019-01-31 | Fortgesetzt | H.C. Wainwright | Buy |
| 2018-03-22 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2018-02-28 | Bestätigt | Cantor Fitzgerald | Buy |
| 2017-08-31 | Eingeleitet | Oppenheimer | Outperform |
| 2017-06-08 | Eingeleitet | Cantor Fitzgerald | Buy |
Alle ansehen
Mesoblast Ltd Adr Aktie (MESO) Neueste Nachrichten
Mesoblast (ASX:MSB) Secures Medicaid Agreement for Ryoncil® - thecapitalclub.com.au
First Three Children to Commence Treatment With Ryoncil® - GlobeNewswire Inc.
UPDATED: Your guide to February Reporting Season 2020 - Morningstar.com.au
21 Best-Performing Small-Cap Stocks for March 2025 - NerdWallet
Why Mesoblast Ltd ADR (NASDAQ: MESO) Is Worth Including On Your Watchlist - Marketing Sentinel
The 98.76% Simple Moving Average of Mesoblast Ltd ADR’s (MESO) Stock in the Past 200 Days - The News Heater
Mesoblast Ltd ADR (NASDAQ:MESO) Shares Are Up 10.24 Percent In A Week – But Can The Gains Continue? - Marketing Sentinel
Why are Mesoblast shares in a trading halt? - The Motley Fool Australia
Mesoblast Limited Initiates Trading Halt Pending Financing Announcement - TipRanks
ASX December health sector winners… and a 91pc drop for a trial-flopped stock - Stockhead
MESO Stock Surges 80% In A Month After FDA Approval Of GVHD Drug - Barchart
Mesoblast (NASDAQ:MESO) Shares Gap UpWhat's Next? - MarketBeat
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
Investors: What’s The Real Deal With W & T Offshore Inc (NYSE: WTI) - Stocks Register
What Analysts Think About TC BioPharm (Holdings) plc ADR (NASDAQ: TCBP)’s Potential Raise - Stocks Register
No Stopping Argo Blockchain Plc ADR (NASDAQ: ARBK)’s Stock Plunged? - Stocks Register
NIO Inc ADR (NYSE: NIO) Stock Forecast: Could Pass $8 In A Year - Stocks Register
If You Don’t Buy Safe Pro Group Inc (NASDAQ: SPAI) Now, You’ll Regret It Later - Stocks Register
What Do Analysts Think About Aspen Aerogels Inc’s (NYSE:ASPN) Future? - Stocks Register
Would I Buy Opendoor Technologies Inc (NASDAQ: OPEN) Stock At Any Time In The Future? - Stocks Register
Tempest Therapeutics Inc (NASDAQ: TPST) Investors Should Be Worried About This. - Stocks Register
Cytek Biosciences, Emergent BioSolutions, Radiopharm Theranostics And Other Big Stocks Moving Higher On Monday - Benzinga
Petco Health and Wellness Co Inc (NASDAQ: WOOF): A Hidden Gem Despite Volatility - Stocks Register
Where Do Analysts See Gamestop Corporation (NYSE: GME) Heading? - Stocks Register
Mesoblast Stock Soars to 52-Week High, Hits $19.15 - Investing.com
Here’s Why Lineage Cell Therapeutics Inc (AMEX: LCTX) Is An Attractive Investment Right Now - Stocks Register
No Stopping Editas Medicine Inc (NASDAQ: EDIT)’s Stock Plunged? - Stocks Register
What Do Analysts Think About Therealreal Inc’s (NASDAQ:REAL) Future? - Stocks Register
What Awaits These 4 Biotech Stocks That More Than Doubled In 2024 - Barchart
Mesoblast shares downgraded to hold by Jefferies By Investing.com - Investing.com South Africa
Why the Mesoblast share price is diving 18% after an FDA win - The Motley Fool Australia
Mesoblast share price rockets 30% on big US FDA news - The Motley Fool Australia
Mesoblast stock soars to 52-week high, hits $12.21 - Investing.com
Mesoblast Stock Soars to 52-Week High, Hits $12.19 - Investing.com
Best Momentum Stocks to Buy for November 26th - Yahoo Finance
Investors Heavily Search Sea Limited Sponsored ADR (SE): Here is What You Need to Know - Yahoo Finance
Mesoblast stock soars to 52-week high, hits $11.1 - Investing.com
Mesoblast files annual report and meeting notice - Investing.com India
JPMorgan Takes Substantial Stake in Mesoblast Ltd - TipRanks
Mesoblast stock soars to 52-week high, hits $8.7 - Investing.com
Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential (NASDAQ:MESO) - Seeking Alpha
What Makes Holcim Ltd Unsponsored ADR (HCMLY) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Mesoblast stock gains momentum ahead of 2025 PDUFA dateJefferies - Investing.com
Australia stocks higher at close of trade; S&P/ASX 200 up 0.50% - Investing.com
Mesoblast: Rolling The Dice On Cellular Medicines (NASDAQ:MESO) - Seeking Alpha
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners - Stockhead
Australia stocks higher at close of trade; S&P/ASX 200 up 0.99% - Investing.com
11 Best ASX Stocks To Buy Now - Yahoo Finance
Sea Limited (SE) to Report Q4 Earnings: What's in Store? - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
10 Best Australian Stocks To Buy - Yahoo Finance
Finanzdaten der Mesoblast Ltd Adr-Aktie (MESO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.05%
1.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):